GT Biopharma Inc. - GTBP STOCK NEWS

GT Biopharma (NASDAQ: GTBP) presented new preclinical data at ASH 2022, showcasing a novel dual antigen targeting strategy for acute myeloid leukemia (AML). The research combines their TriKE technology with Fate Therapeutics' iPSC-derived CAR NK cells. Preclinical models showed that α3 MICA/B iNK cells displayed significant anti-leukemic activity against AML cell lines, enhanced in combination with anti-CD33 TriKE, GTB-3650. The study indicates potential to improve patient outcomes by addressing AML's clinical heterogeneity.

GT Biopharma (NASDAQ: GTBP) recently presented two posters at the Society for Immunotherapy of Cancer’s 37th Annual Meeting, showcasing its TriKE^® platform aimed at treating mesothelioma and prostate cancer. The presentations discussed the efficacy of novel tri-specific killer engagers (TriKEs) targeting mesothelin and prostate-specific membrane antigen (PSMA). Both TriKEs demonstrated potential in enhancing NK cell activity against resistant cancer types and are set for further pre-clinical studies and IND applications in 2023, marking significant progress for the company's innovative immuno-oncology therapies.

GT Biopharma announced the presentation of new research at ASH 2022, focusing on a dual antigen targeting method for treating acute myeloid leukemia (AML). The study combines GTB-3650, a CD33 targeting TriKE, with Fate Therapeutics' iPSC-derived CAR NK cells targeting MICA/B. Preclinical data indicate that the combination enhances the anticancer activity of CAR NK cells against AML cell lines. The poster presentation will occur on December 12, 2022, in New Orleans.

GT Biopharma (GTBP) announced its third quarter fiscal 2022 results, reporting a cash position of $20.8 million as of September 30, 2022, down from $23.7 million in June 2022. This funding is anticipated to support operations into 2023. R&D expenses increased to $2.8 million for Q3 2022, a rise of $1.8 million year-over-year, reflecting investments in developing second-generation TriKE® products. The company recorded a net loss of $6.9 million for the quarter, compared to a $5.5 million loss in Q3 2021.

GT Biopharma announced two poster presentations for the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022) in Boston from November 8-12, 2022. The presentations will feature preclinical data on their tri-specific NK cell engagers targeting mesothelioma and prostate cancer. The first poster, focusing on mesothelioma, will be presented by Pippa Kennedy and Martin Felices, while the second, addressing prostate cancer, will be presented by Shee Kwan Phung and Martin Felices. These developments showcase GT Biopharma's commitment to advancing immunotherapy.

GT Biopharma, Inc. (NASDAQ: GTBP) has adjourned its 2022 Special Shareholders Meeting to October 10, 2022, at 11 a.m. PST due to a lack of quorum. The meeting aims to ratify the inclusion of discretionary votes by brokers for a proposal to reduce the company’s authorized shares of common stock from 750 million to 250 million. Shareholders on record as of August 8, 2022, are encouraged to vote by 11:59 p.m. PST on October 9, 2022. Those who have already voted do not need to recast their votes unless wishing to change them.

GT Biopharma (NASDAQ: GTBP) announced key findings from its accepted abstract at the ESMO Congress 2022, highlighting the efficacy of its product candidate GTB-5550. This compound specifically targets B7-H3+ solid tumors, generating a strong NK cell proliferation signal surpassing that of IL-15 alone. GTB-5550 has shown promising results in inducing NK cell degranulation and interferon gamma production against various malignancies. Ongoing in vivo activity in human tumor xenogeneic models further supports these findings. The company anticipates submitting an IND application in 2023.

GT Biopharma, Inc. (NASDAQ: GTBP) will present at H.C. Wainwright’s 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, at the Lotte New York Palace. The presentation is set for September 13, from 10:30 to 11:00 am EDT. This clinical-stage immuno-oncology company focuses on innovative therapeutics utilizing its proprietary NK cell engager, TriKE^®. Management will also engage in 1x1 meetings with attendees. A webcast of the presentation will be available for replay for 90 days following the event.

GT Biopharma, Inc. (NASDAQ: GTBP) announced a Settlement and Investment Agreement with Cytovance Biologics for the registration of its investigational new drug GTB-3650. The IND application with the FDA is expected by March 31, 2023. GTB-3650 aims to treat relapsed/refractory acute myelogenous leukemia and high-risk myelodysplastic syndrome, and offers several advantages over its predecessor, GTB-3550, including improved potency and a fully owned proprietary molecule. Payments to Cytovance will be limited to 4.9% of total shares outstanding.